SchillaciO, DanieliR, FilippiL, et al.Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res, 2007; 27(1B):557–562.
2.
GuoC, ZhangC, LiuJ, et al.Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis. Nucl Med Commun, 2016; 37(7):675–688; doi: 10.1097/MNM.0000000000000502
3.
Pérez-GarcíaJM, GebhartG, Ruiz BorregoM, et al.Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): A multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncol, 2021; 22(6):858–871; doi: 10.1016/S1470-2045(21)00122-4
4.
GebhartG, KeyaertsM, GuiotT, et al.Optimal [18F]FDG PET/CT cutoff for pathologic complete response in HER2-Positive early breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab in the PHERGain trial. J Nucl Med, 2024:jnumed.123.266384; doi: 10.2967/jnumed.123.266384
5.
Pérez-GarcíaJM, CortésJ, Ruiz-BorregoM, et al.3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): A randomised, open-label, phase 2 trial. Lancet, 2024; S0140-6736(24):00054–0; doi: 10.1016/S0140-6736(24)00054-0
6.
KollaL, ParikhRB. Uses and limitations of artificial intelligence for oncology. Cancer, 2024; doi: 10.1002/cncr.35307
7.
LiuJ, ZhangZ, BianH, et al.Predictive value of radiomic signature based on 2-[18F]FDG PET/CT in HER2 status determination for primary breast cancer with equivocal IHC results. Eur J Radiol, 2023; 167:111050; doi: 10.1016/j.ejrad.2023.111050
8.
AlhuseinalkhudhurA, LindmanH, LissP, et al.Human epidermal growth factor receptor 2–targeting [68 Ga]Ga-ABY-025 PET/CT predicts early metabolic response in metastatic breast cancer. J Nucl Med, 2023; 64(9):1364–1370; doi: 10.2967/jnumed.122.265364
